Last updated: February 15, 2026
What is NDC 60219-2039?
NDC 60219-2039 corresponds to Zirabev (bevacizumab-bvzr), a biosimilar of Avastin. Approved by the FDA in October 2021, Zirabev targets multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, and glioblastoma.
Market Overview
Market Size and Penetration
The global oncology biosimilars market was valued at approximately $4.2 billion in 2022. With biosimilars accounting for 15% of oncology drug sales, Zirabev's market share is projected to rise as generic entry pressures increase.
In the US, Avastin's sales exceeded $7 billion annually pre-expiry. Biosimilar competition could lead to a 20-30% reduction in Avastin's US sales over five years as hospitals switch to biosimilars.
Competition Landscape
Key competitors include:
- Amgen's Mvasi (bevacizumab-awwb): Launched in 2019.
- Samsung Bioepis/Celltrion's Zirabev: Launched in 2021.
- Pfizer's Zirabev: Launch timeline aligned with FDA approval.
Each biosimilar is priced 15-25% lower than Avastin, a typical discount range for oncology biosimilars.
Pricing Dynamics
Historical Pricing Trends
- Avastin's average wholesale price (AWP): ~$6,000 per 400 mg vial.
- Biosimilar prices: 15-25% below AWP, approximately $4,500–$5,100 per vial.
Current Price and Discount Strategies
Market entry reduces price by approximately 20% relative to innovator. Hospitals and payers negotiate discounts, which further reduce effective prices.
Projected Price Trends
- Year 1 post-launch: Biosimilar priced at 15-20% below Avastin, around $4,000–$4,500 per vial.
- Year 3: Volume growth increases, driving prices down another 5%, stabilizing around $3,800–$4,200.
- Year 5: An anticipated 25-30% decline from baseline biosimilar price, with prices approaching $3,200 per vial.
Revenue Projections
Assuming a market share of 25% within 3 years and 40% by Year 5, and considering pre-expiry annual Avastin sales in the US at $3 billion, biosimilar sales could approximate:
| Year |
Market Share |
Estimated Biosimilar Sales |
Price per Vial |
Revenue Projection |
| Year 1 |
10% |
~$300 million |
$4,500 |
~$135 million |
| Year 3 |
25% |
~$750 million |
$4,000 |
~$300 million |
| Year 5 |
40% |
~$1.2 billion |
$3,500 |
~$420 million |
Note: These figures assume an unchanged overall market size and do not account for potential market expansion into new indications or increased biosimilar adoption.
Regulatory and Market Challenges
- Physician Acceptance: Prescriber confidence in biosimilars remains variable, potentially restraining rapid uptake.
- Payer Policies: Favor biosimilar substitution and formulary inclusion, which can accelerate price erosion.
- Manufacturing and Supply: Consistent supply is critical; disruptions can impact pricing and market share.
Key Takeaways
- Zirabev entered a competitive biosimilar market with initial discounts around 15-20%.
- The biosimilar's market share is expected to grow steadily, influencing price reductions.
- Effective pricing will likely decline from ~$4,500 per vial at launch to approximately $3,200–$3,500 in five years.
- Revenue potential hinges on market penetration, prescriber acceptance, and payer policies.
- The biosimilar market will continue evolving as new competitors and indications emerge.
FAQs
-
What factors influence biosimilar price declines?
Competition, payer negotiation, prescriber acceptance, and supply chain stability mainly drive price decreases.
-
How does Zirabev compare to other bevacizumab biosimilars in price?
Zirabev is generally priced 15-20% below the original Avastin. Its pricing aligns closely with Amgen's Mvasi and Samsung Bioepis' Zirabev.
-
What is the expected market share for Zirabev within five years?
A 40-50% market share in the oncology biosimilar segment is plausible given historical uptake patterns.
-
How do regulatory policies impact biosimilar domestication?
Payer policies promoting biosimilar substitution and accelerated approval pathways facilitate faster market penetration.
-
What determines revenue growth for Zirabev?
Revenue growth depends on market adoption, volume increases, and pricing stability over the product lifecycle.
Sources
[1] EvaluatePharma. "Global Oncology Biosimilars Market Report." 2022.
[2] IQVIA. "US Oncology Market Trends." 2022.
[3] FDA. "Zirabev (bevacizumab-bvzr) Approval Documents." October 2021.
[4] MarketWatch. "Biosimilars in Oncology: Market Dynamics." 2022.
[5] Amgen. "Mvasi (bevacizumab-awwb) Pricing and Market Data." 2022.
